We describe a case of renal cell carcinoma with metastasis to the penis clinically presenting with priapism. Six such cases found in the literature are reviewed. Neoplastic disease is far advanced in these cases and therapy is only palliative.
We describe a case of renal cell carcinoma with metastasis to the penis clinically presenting with priapism. Six such cases found in the literature are reviewed. Neoplastic disease is far advanced in these cases and therapy is only palliative.KEY WORDS: malignant priapism, metastatic disease of penis, renal cell carcinoma metastatic to penis, unusual renal cancer metastasis
The once-daily alpha 1 blocker terazosin was administered to 36 men with symptomatic benign prostatic hyperplasia (BPH) who had previously been scheduled for transurethral resection of the prostate (TURP). At 3 months, terazosin at 5 mg q.d. produced improvements in symptom scores, peak urinary flow rates, mean urinary flow rates, and residual urine. These improvements were maintained at 6 and 9 months. Terazosin also proved to be well tolerated, with no cases of hypotension or erectile dysfunction. We conclude that terazosin is effective in relieving obstructive urinary symptoms of BPH and that it allows many patients to be placed in a "holding pattern," allowing surgery to be delayed until the disease progresses. The use of terazosin also increased the capabilities of our urologic clinic. By reducing the urgency of surgery, it allowed us to schedule TURPs more conveniently and thereby accommodate more prostate surgery within the limited resources of our clinic. As a result, the use of terazosin saved considerable CHAMPUS dollars that would otherwise have been lost to the system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.